Dehradun-based health-tech startup Sunfox Technologies has secured INR 15 crore in a pre-Series A funding round led by Venture Catalysts to drive global expansion, focusing on scaling its health-tech innovation, the Spandan ECG device, which plays a critical role in early detection of heart conditions.
Finvolve, through the IA Growth Opportunities Fund I and Brew Opportunities Fund, Universal Group, RP Singhvi Group, and several high-net-worth individuals (HNIs), also participated in the round. The funding is set to drive Sunfox’s expansion within India and internationally.
This fresh investment follows a previous INR 5 crore infusion from the United States Agency For International Development (USAID) through SAMRIDH Health and LetsVenture, bringing the total raised in this round to INR 20 crore.
The capital will be used to scale Sunfox’s flagship product, Spandan, a smartphone-based portable ECG device. Spandan delivers clinically accurate 12-lead ECG readings, enabling users to detect heart attacks and monitor cardiac health in real time.
Rajat Jain, CEO of Sunfox, said, “This capital injection will enable us to scale rapidly, both in India and internationally. It will fuel our growth and bring Spandan into homes and clinics worldwide. We envision a future where heart attacks are as preventable as fevers, with Spandan becoming as ubiquitous as a household thermometer.”
Sunfox, Innovation and Global Recognition
Co-founded in 2016 by Rajat Jain, Arpit Jain, Saurabh Badola, Nitin Chandola, and Sabit Rawat, Sunfox Technologies has rapidly gained attention for its cutting-edge healthcare innovations. Spandan has already been used by over 30,000 individuals across 20 countries and has reportedly saved more than 10,000 lives through early detection of heart conditions. As India faces a rise in heart attack cases post-COVID-19, Spandan’s role in early diagnosis becomes increasingly critical.
Sunfox Technologies rose to fame after its appearance on Shark Tank India, where it secured investments from all five sharks—Namita Thapar, Peyush Bansal, Anupam Mittal, Vineeta Singh, and Ghazal Alagh. The company has since established an advanced in-house R&D and manufacturing facility in Dehradun and received recognition from prestigious global institutions like Oxford and Wharton.
Apoorva Ranjan Sharma, Co-founder and Managing Director of Venture Catalysts, said, “Sunfox represents the future of cardiac care. We are proud partners in their journey and are excited to see them reach new heights with Spandan. Their mission to make heart health accessible globally is truly inspiring, and we believe they are poised to reshape the healthcare landscape.”
Sunfox’s innovative approach and commitment to improving cardiac health have positioned it as a leader in the health-tech space. With this latest funding round, the company is poised to make significant strides in domestic and international markets, bringing life-saving technology to a broader audience.
Stay ahead of the curve and follow IndiaTechDesk on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in India.
Read More:
- Byju’s replace Paytm to become India’s most valuable startup
- How is Skilfinity Assisting Brands to be Visible and Popular Online?
- Zepto, a Quick Commerce Platform Secures $200 Million in Series-E Funding, Achieves Unicorn Status
- Indian Government will Provide 50 Lakh under Grant Program to Boost Technical Textiles Startups
- Super-app build up: Tata Digital on buying spree; gets a stake in online pharmacy 1MG
